top of page

AD Background

Mild Cognitive Impairment is the First Sign

Mild cognitive impairment (MCI): a term used to describe a state of cognitive decline representing a transition between normal cognition and dementia. 

Approximately 15-20% of people age 65 or older have MCI.

MCI causes cognitive changes that are serious enough to be noticed by the individuals experiencing them or to other people, but the changes are not severe enough to interfere with daily life or independent function.

Alzheimer’s Disease is the Most Common Cause

of Dementia

•Although there are various forms of dementia, around 70% of cases are due to Alzheimer’s disease.

 

•Of the remaining cases, the second most common type is vascular dementia.

•Due to longer life expectancies and the baby boomer population, the percentage of Americans living with this disease will increase in the upcoming years.

The 6th Leading Cause Of Death In The United States

1 in 3 seniors dies with Alzheimer’s  or Another Dementia

5.7 Million Seniors are Living with Alzheimer’s.

It is estimated that over 16 million people provide “unpaid” care for people with Alzheimer’s  and other dementias. 

Chances Are You Know Or Knew Someone With Alzheimer’s

Current Theories Are Not Working

& Billions Of Dollars Are Being Spent

 

As people live longer this disease is affecting more and more people.

 

From 2000 – 2015:

•Deaths from Alzheimer’s disease increased 123%

•Deaths from heart disease decreased by 11%

PFIZER HALTS ALZHEIMER’S RESEARCH 

Company’s failedAlzheimer’s 

disease trials NPR 1-8-18

AXOVANT STOCK TUMBLES 

                     Company abandons its banner                            Alzheimer’s drug intepirdine   

WSJ BUSINESS 2-12-18

BIOGEN STOCK TUMBLES

After company ends 2 Alzheimer’s trials

of aducanumab, a blow to hopes for a new treatment

WALL STREET JOURNAL 3-21-19

MORE DRUGS FLUNK FINAL STAGES

Some scientists believe the whole amyloid hypothesis is flawed

FINANICAL TIMES 3-11-18

END OF THE EXPEDITION

Eli Lilly’s antibody not enough to reach statistical significance for solanezumab             

ALZFORUM NETWORKING FOR A CURE 1-24-2018

MERCK DISCONTINUES APECS STUDY

For the treatment of prodromal   Alzheimer’s disease

BUSINESS WIRE 2-13-18

Alzheimer's Summary

 

Alzheimer’s Disease (AD) afflicts an estimated 57 million people globally, a number which could rise to 150+ million by 2050 if a treatment is not implemented before then.

Care of AD patients costs America an estimated $214 billion annually and rising.

Currently, there are approximately 9 FDA approved medications for AD, which are modestly effective and very costly.

FDA recently controversially approved Aducanumab for AD treatment; annual estimated cost is approximately $60,000 per year and must be given by IV.  Widespread use of this drug would cause financial distress for Medicare/Medicaid.

​The total AD therapeutics world-wide is expected to reach approximately $13.5 billion dollars annually with 9% growth rate.

bottom of page